Literature DB >> 17488771

Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.

Laurent Bonello1, Pascal Sbragia, Nicolas Amabile, Olivier Com, Sandrine V Pierre, Samuel Levy, Franck Paganelli.   

Abstract

OBJECTIVE: To evaluate the effect of pre-procedural acute oral administration of trimetazidine (TMZ) on percutaneous coronary intervention (PCI)-induced myocardial injury.
DESIGN: Single-centre, prospective, randomised evaluation study.
SETTING: Patients with stable angina pectoris and single-vessel disease undergoing PCI. PATIENTS: 582 patients were prospectively randomised. Patients who underwent more than one inflation during PCI were excluded, resulting in 266 patients randomly assigned to 2 groups.
INTERVENTIONS: Patients were randomly assigned to receive or not an acute loading dose of 60 mg of TMZ prior to intervention. MAIN OUTCOME: The frequency and the increase in the level of cardiac troponin Ic (cTnI) after successful PCI. cTnI levels were measured before and 6, 12, 18 and 24 h after PCI.
RESULTS: 136 patients were assigned to the TMZ group and 130 to the control group. Although no statistically significant difference was observed in the frequency of cTnI increase between the two groups, post-procedural cTnI levels were significantly reduced in the TMZ group at all time points (6 h: mean (SD) 4.2 (0.8) vs 1.7 (0.2), p<0.001; 12 h: 5.5 (1.5) vs 2.3 (0.4), p<0.001; 18 h: 9 (2.3) vs 3 (0.5), p<0.001; and 24 h: 3.2 (1.2) vs 1 (0.5), p<0.001). Moreover, the total amount of cTnI released after PCI, as assessed by the area under the curve of serial measurement, was significantly reduced in the TMZ group (p<0.05).
CONCLUSION: Pre-procedural acute oral TMZ administration significantly reduces PCI-induced myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488771      PMCID: PMC1955183          DOI: 10.1136/hrt.2006.107524

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  21 in total

1.  A randomized trial of stenting with or without balloon predilation for the treatment of coronary artery disease.

Authors:  L I Kovar; E S Monrad; W Sherman; S Kunchithapatham; K L Ravi; W Gotsis; G Silverman; D L Brown
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

2.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty).

Authors:  S C Smith; J T Dove; A K Jacobs; J W Kennedy; D Kereiakes; M J Kern; R E Kuntz; J J Popma; H V Schaff; D O Williams; R J Gibbons; J P Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

3.  Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging.

Authors:  Joseph B Selvanayagam; Italo Porto; Keith Channon; Steffen E Petersen; Jane M Francis; Stefan Neubauer; Adrian P Banning
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

4.  Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results.

Authors:  P Di Pasquale; P Lo Verso; V Bucca; S Cannizzaro; S Scalzo; G Maringhini; R Rizzo; S Paterna
Journal:  Cardiovasc Drugs Ther       Date:  1999-09       Impact factor: 3.727

5.  Acute and subacute stent occlusion; risk-reduction by ionic contrast media.

Authors:  B Scheller; B Hennen; A Pohl; H Schieffer; T Markwirth
Journal:  Eur Heart J       Date:  2001-03       Impact factor: 29.983

Review 6.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

7.  Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury.

Authors:  Laurent Argaud; Ludovic Gomez; Odile Gateau-Roesch; Elisabeth Couture-Lepetit; Joseph Loufouat; Dominique Robert; Michel Ovize
Journal:  J Mol Cell Cardiol       Date:  2005-10-21       Impact factor: 5.000

8.  Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals.

Authors: 
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

9.  A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction.

Authors:  P G Steg; G Grollier; P Gallay; M Morice; G J Karrillon; H Benamer; C Kempf; T Laperche; P Arnaud; P Sellier; C Bourguignon; C Harpey
Journal:  Int J Cardiol       Date:  2001-02       Impact factor: 4.164

10.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

Authors:  P F Kantor; A Lucien; R Kozak; G D Lopaschuk
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

View more
  10 in total

1.  Measurement and prevention of myocardial injury during percutaneous coronary intervention.

Authors:  Patrick Schiano; Philippe Gabriel Steg
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

Review 2.  Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.

Authors:  Victor Soukoulis; William E Boden; Sidney C Smith; Patrick T O'Gara
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

3.  Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry.

Authors:  Jeong Su Kim; Chang Hoon Kim; Kook Jin Chun; June Hong Kim; Yong Hyun Park; Jun Kim; Jin Hee Choi; Sang Hyun Lee; Eun Jung Kim; Dae Gon Yu; Eun Young Ahn; Myung Ho Jeong
Journal:  Clin Res Cardiol       Date:  2013-08-28       Impact factor: 5.460

4.  Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1.

Authors:  Jing Chen; Jinsheng Lai; Lei Yang; Guoran Ruan; Sandip Chaugai; Qin Ning; Chen Chen; Dao Wen Wang
Journal:  Br J Pharmacol       Date:  2015-12-25       Impact factor: 8.739

Review 5.  Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.

Authors:  Ying Zhang; Xiao-Juan Ma; Da-Zhuo Shi
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

Review 6.  Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.

Authors:  Csaba A Dézsi
Journal:  Am J Ther       Date:  2016 May-Jun       Impact factor: 2.688

Review 7.  Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.

Authors:  Jamshed J Dalal; Sundeep Mishra
Journal:  Indian Heart J       Date:  2017-04-29

8.  Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.

Authors:  Mohamed Shehata
Journal:  Cardiol Res       Date:  2014-05-15

Review 9.  Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

Authors:  Andromachi Reklou; Michael Doumas; Konstantinos Imprialos; Konstantinos Stavropoulos; Dimitris Patoulias; Vasilios G Athyros
Journal:  Open Cardiovasc Med J       Date:  2018-03-30

Review 10.  New directions in the treatment of heart failure: targeting free fatty acid oxidation.

Authors:  Gabriele Fragasso; Roberto Spoladore; Giorgio Bassanelli; Amarild Cuko; Chiara Montano; Anna Salerno; Alberto Margonato
Journal:  Curr Heart Fail Rep       Date:  2007-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.